Moreover, visualization of the network overlaps between NAFLD signatures and drug signatures revealed more extensive disease network connections for fluvastatin than for aspirin (Figures 4G and 4H), and the signatures of the two drugs connected to pathways involved in NAFLD such as PPAR signaling pathways and fatty acid and steroid biosynthesis. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.